Spencer C Wei
Overview
Explore the profile of Spencer C Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
3300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gowen B, Melton K, Leong W, Khekare P, McCawley S, Chan J, et al.
PLoS One
. 2025 Feb;
20(2):e0317745.
PMID: 39992915
Therapeutic targeting of the adenosine deaminase ADAR has great potential in cancer and other indications; however, it remains unclear what approach can enable effective and selective therapeutic inhibition. Herein, we...
2.
Wei S, Cantor A, Walleshauser J, Mepani R, Melton K, Bans A, et al.
bioRxiv
. 2025 Jan;
PMID: 39803585
Genetic medicines, including CRISPR/Cas technologies, extend tremendous promise for addressing unmet medical need in inherited retinal disorders and other indications; however, there remain challenges for the development of therapeutics. Herein,...
3.
Gowen B, Khekare P, McCawley S, Melton K, Soares C, Chan J, et al.
CRISPR J
. 2024 Sep;
7(6):306-309.
PMID: 39308435
No abstract available.
4.
Axelrod M, Meijers W, Screever E, Qin J, Carroll M, Sun X, et al.
Nature
. 2022 Nov;
611(7937):818-826.
PMID: 36385524
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The pathogenesis of ICI-associated myocarditis (ICI-MC) is...
5.
Wei S
Cancer Immunol Res
. 2022 Nov;
11(1):3.
PMID: 36318053
Defining the mechanisms of action of immune checkpoint blockade therapies is essential for effectively designing combination therapeutic approaches and developing the next generation of immunotherapies. In this issue, Schaafsma and...
6.
Wei S, Mancuso J, Daver N, Allison J
Blood Cancer Discov
. 2022 Jan;
2(6):551-554.
PMID: 35015675
An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and...
7.
Wei S, Meijers W, Axelrod M, Anang N, Screever E, Wescott E, et al.
Cancer Discov
. 2020 Dec;
11(3):614-625.
PMID: 33257470
Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of...
8.
Ma Y, Li J, Wang H, Chiu Y, Kingsley C, Fry D, et al.
Gastroenterology
. 2020 Mar;
159(1):306-319.e12.
PMID: 32179091
Background & Aims: Advanced pancreatic ductal adenocarcinoma (PDAC) is resistant to therapy, including immune checkpoint inhibitors. We evaluated the effects of a neutralizing antibody against programmed cell death 1 (PD-1)...
9.
Wei S, Anang N, Sharma R, Andrews M, Reuben A, Levine J, et al.
Proc Natl Acad Sci U S A
. 2019 Oct;
116(45):22699-22709.
PMID: 31636208
Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti-CTLA-4 and anti-PD-1 blockade therapy has enhanced efficacy,...
10.
Wei S, Sharma R, Anang N, Levine J, Zhao Y, Mancuso J, et al.
Immunity
. 2019 Mar;
50(4):1084-1098.e10.
PMID: 30926234
Co-stimulation regulates T cell activation, but it remains unclear whether co-stimulatory pathways also control T cell differentiation. We used mass cytometry to profile T cells generated in the genetic absence...